Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells

Fei Ting Hsu, Betty Chang, I. Tsang Chiang, Tai Hsien Wu, Jeng Jong Hwang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background/Aim: Although anticancer effects of sorafenib on renal, liver and colon carcinomas are wellknown, its combination effect with ionizing radiation on oral squamous cell carcinoma (OSCC) is unclear. Herein human SAS cells, an OSCC cell line, were used in order to elucidate this combination effect. Materials and Methods: Both SAS and SAS/nuclear factor kappa-B-luciferase (SAS/NF-κBluc2) cell lines were used in the study. Cell viability, NF-κB activation, and protein expression of NF-κB downstream effectors were determined by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide assay, NF-κB-luc2 reporter gene system, NF-κB/DNA binding activity and western blotting. Results: Sorafenib significantly increased radiationinduced cytotoxicity and apoptosis via both mitochondrialdependent and independent pathways. In addition, NF-κB activity and downstream effector protein expression induced by radiation was suppressed by sorafenib in SAS/NF-κB-luc2 cells. Conclusion: Combination of sorafenib with radiation for the treatment of human OSCC shows a synergistic effect via suppression of radiation-induced NF-κB activity and its regulated downstream effector proteins.

Original languageEnglish
Pages (from-to)925-934
Number of pages10
JournalIn Vivo
Volume28
Issue number5
Publication statusPublished - Sep 1 2014
Externally publishedYes

Fingerprint

Mouth Neoplasms
Ionizing radiation
Ionizing Radiation
Cells
Squamous Cell Carcinoma
Radiation
Cell Line
Proteins
NF-kappa B
Cytotoxicity
Luciferases
Reporter Genes
Liver
Assays
Cell Survival
Colon
Genes
Western Blotting
Chemical activation
Apoptosis

Keywords

  • Human oral squamous cell carcinoma
  • NF-κB
  • Radiation
  • Sorafenib

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

Hsu, F. T., Chang, B., Chiang, I. T., Wu, T. H., & Hwang, J. J. (2014). Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells. In Vivo, 28(5), 925-934.

Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells. / Hsu, Fei Ting; Chang, Betty; Chiang, I. Tsang; Wu, Tai Hsien; Hwang, Jeng Jong.

In: In Vivo, Vol. 28, No. 5, 01.09.2014, p. 925-934.

Research output: Contribution to journalArticle

Hsu, FT, Chang, B, Chiang, IT, Wu, TH & Hwang, JJ 2014, 'Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells', In Vivo, vol. 28, no. 5, pp. 925-934.
Hsu FT, Chang B, Chiang IT, Wu TH, Hwang JJ. Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells. In Vivo. 2014 Sep 1;28(5):925-934.
Hsu, Fei Ting ; Chang, Betty ; Chiang, I. Tsang ; Wu, Tai Hsien ; Hwang, Jeng Jong. / Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells. In: In Vivo. 2014 ; Vol. 28, No. 5. pp. 925-934.
@article{0ee39a237e524214b9d7b6e6c2c77d8e,
title = "Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells",
abstract = "Background/Aim: Although anticancer effects of sorafenib on renal, liver and colon carcinomas are wellknown, its combination effect with ionizing radiation on oral squamous cell carcinoma (OSCC) is unclear. Herein human SAS cells, an OSCC cell line, were used in order to elucidate this combination effect. Materials and Methods: Both SAS and SAS/nuclear factor kappa-B-luciferase (SAS/NF-κBluc2) cell lines were used in the study. Cell viability, NF-κB activation, and protein expression of NF-κB downstream effectors were determined by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide assay, NF-κB-luc2 reporter gene system, NF-κB/DNA binding activity and western blotting. Results: Sorafenib significantly increased radiationinduced cytotoxicity and apoptosis via both mitochondrialdependent and independent pathways. In addition, NF-κB activity and downstream effector protein expression induced by radiation was suppressed by sorafenib in SAS/NF-κB-luc2 cells. Conclusion: Combination of sorafenib with radiation for the treatment of human OSCC shows a synergistic effect via suppression of radiation-induced NF-κB activity and its regulated downstream effector proteins.",
keywords = "Human oral squamous cell carcinoma, NF-κB, Radiation, Sorafenib",
author = "Hsu, {Fei Ting} and Betty Chang and Chiang, {I. Tsang} and Wu, {Tai Hsien} and Hwang, {Jeng Jong}",
year = "2014",
month = "9",
day = "1",
language = "English",
volume = "28",
pages = "925--934",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells

AU - Hsu, Fei Ting

AU - Chang, Betty

AU - Chiang, I. Tsang

AU - Wu, Tai Hsien

AU - Hwang, Jeng Jong

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Background/Aim: Although anticancer effects of sorafenib on renal, liver and colon carcinomas are wellknown, its combination effect with ionizing radiation on oral squamous cell carcinoma (OSCC) is unclear. Herein human SAS cells, an OSCC cell line, were used in order to elucidate this combination effect. Materials and Methods: Both SAS and SAS/nuclear factor kappa-B-luciferase (SAS/NF-κBluc2) cell lines were used in the study. Cell viability, NF-κB activation, and protein expression of NF-κB downstream effectors were determined by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide assay, NF-κB-luc2 reporter gene system, NF-κB/DNA binding activity and western blotting. Results: Sorafenib significantly increased radiationinduced cytotoxicity and apoptosis via both mitochondrialdependent and independent pathways. In addition, NF-κB activity and downstream effector protein expression induced by radiation was suppressed by sorafenib in SAS/NF-κB-luc2 cells. Conclusion: Combination of sorafenib with radiation for the treatment of human OSCC shows a synergistic effect via suppression of radiation-induced NF-κB activity and its regulated downstream effector proteins.

AB - Background/Aim: Although anticancer effects of sorafenib on renal, liver and colon carcinomas are wellknown, its combination effect with ionizing radiation on oral squamous cell carcinoma (OSCC) is unclear. Herein human SAS cells, an OSCC cell line, were used in order to elucidate this combination effect. Materials and Methods: Both SAS and SAS/nuclear factor kappa-B-luciferase (SAS/NF-κBluc2) cell lines were used in the study. Cell viability, NF-κB activation, and protein expression of NF-κB downstream effectors were determined by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide assay, NF-κB-luc2 reporter gene system, NF-κB/DNA binding activity and western blotting. Results: Sorafenib significantly increased radiationinduced cytotoxicity and apoptosis via both mitochondrialdependent and independent pathways. In addition, NF-κB activity and downstream effector protein expression induced by radiation was suppressed by sorafenib in SAS/NF-κB-luc2 cells. Conclusion: Combination of sorafenib with radiation for the treatment of human OSCC shows a synergistic effect via suppression of radiation-induced NF-κB activity and its regulated downstream effector proteins.

KW - Human oral squamous cell carcinoma

KW - NF-κB

KW - Radiation

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84918538480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918538480&partnerID=8YFLogxK

M3 - Article

C2 - 25189909

AN - SCOPUS:84918538480

VL - 28

SP - 925

EP - 934

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 5

ER -